Le Lézard
Classified in: Health, Science and technology, Business
Subject: ERN

Ipsidy Announces Results for Year Ended December 31, 2017


LONG BEACH, New York, March 15, 2018 /PRNewswire/ -- Ipsidy Inc. (www.ipsidy.com) (OTCQB: IDTY), (formerly known as ID Global Solutions Corporation), a provider of secure, biometric identification, identity management and electronic transaction processing services, today announced its results for the year ended December 31, 2017.

Financial Highlights for the Year Ended December 31, 2017

The combination of the above events resulted in the substantial improvement in the Company's balance sheet and provided near-term working capital.

Refer to Table 1 for reconciliation of net income to Adjusted EBITDA (a non-GAAP measure).

Operational Highlights

"2017 was a year of transformational change," said Philip Beck, Chairman and Chief Executive Officer of Ipsidy. "The Company was recapitalized, management was reorganized and the Ipsidy team strengthened. We continue to enhance our identity transaction platform, in order to create trusted transactions to approve everyday events.  Our platform enables customers to choose the levels of friction and assurance that are appropriate to their business. We are looking forward to an exciting year of progress."

We are building upon our existing capabilities in biometric identification and multi-factor identity authentication and management solutions to develop an identity transaction platform for our business customers. The platform is being designed to enable the end users of our business customers to more easily authenticate their identity through a mobile phone or portable device of their choosing (as opposed to dedicated hardware). Our system enables participants to complete transactions with a digitally signed authentication response, including the underlying transaction data and embedded attributes of the participant's identity.

We believe that it is essential that businesses and consumers know who is on the other side of an electronic transaction and have an audit trail, proving that the identity of the other party was duly authenticated. We are continuing to enhance solutions to provide our customers with the next level of transaction security, control and certainty. Our platform uses biometric and multi-factor identity management solutions, which are intended to support a wide variety of electronic transactions. We define "electronic transactions" in the broadest sense to include not only financial transactions (i.e. exchanges of value in all of their forms), and legal transactions (e.g. approving the release of personal or other confidential data or the execution of documents), but also access control to physical environments (e.g. border crossings and secure areas at offices, data centers and other sensitive locations) and digital environments (e.g. accessing account information, voting systems, email systems and controlling data network log-ins).

Additional analysis of the Company's performance can be found in "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in the Quarterly Report on Form 10-K for the year ended December 31, 2017 filed at www.sec.gov and posted on the Company's investor relations website.

About Ipsidy:

Ipsidy Inc (OTCQB: IDTY) www.ipsidy.com (formerly known as ID Global Solutions Corporation OTC: IDGS) is a provider of secure, biometric identification, identity management and electronic transaction processing services. Ipsidy is headquartered in New York and has operating subsidiaries: MultiPay in Colombia, www.multipay.com.co and Cards Plus in South Africa, www.cardsplus.co.za. Our identity transaction platform creates a trusted transaction, embedding authenticated identity and event details with a digital signature and using a participant's mobile device to approve everyday transactions. Our platform is being designed to use biometric and multi-factor identity management solutions, which are intended to support a wide variety of electronic transactions. We believe that it is essential that businesses and consumers know who is on the other side of an electronic transaction and have an audit trail, proving that the identity of the other party was duly authenticated. We continue to enhance our solutions to provide our customers with the next level of transaction security, control and certainty over everyday transactions. Further information on Ipsidy can be found at www.ipsidy.com or contact us at [email protected].

Notice Regarding Forward-Looking Statements.

Information contained in this announcement may include "forward-looking statements." All statements other than statements of historical facts included herein, including, without limitation, those regarding the financial position, business strategy, plans and objectives of management for future operations of both Ipsidy and its business partners, future service launches with customers, the outcome of pilots and new initiatives and customer pipeline are forward-looking statements. Such forward-looking statements are based on a number of assumptions regarding Ipsidy present and future business strategies, and the environment in which Ipsidy expects to operate in the future, which assumptions may or may not be fulfilled in practice. Implementation of some or all of the new services referred to is subject to regulatory or other third party approvals. Actual results may vary materially from the results anticipated by these forward-looking statements as a result of a variety of risk factors, including the risk that implementation, adoption and offering of the service by customers, consumers and others may take longer than anticipated, or may not occur at all; changes in laws, regulations and practices; changes in domestic and international economic and political conditions and others. Additional risks may arise with respect to commencing operations in new countries and regions, of which Ipsidy is not fully aware at this time. See the Company's Annual Report Form 10-K for the Fiscal Year ended December 31, 2017 filed at www.sec.gov for other risk factors which investors should consider. These forward-looking statements speak only as to the date of this announcement and cannot be relied upon as a guide to future performance. Ipsidy expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any changes in its expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based.

Non-GAAP Financial Information.

The Company provides certain non-GAAP financial measures in this statement. Management believes that Adjusted EBITDA, when viewed with our results under GAAP and the accompanying reconciliations, provides useful information about our period-over-period results. Adjusted EBITDA is presented because management believes it provides additional information with respect to the performance of our fundamental business activities and is also frequently used by securities analysts, investors and other interested parties in the evaluation of comparable companies. We also rely on Adjusted EBITDA as a primary measure to review and assess the operating performance of our company and our management team in connection with our executive compensation. These non-GAAP key business indicators, which include Adjusted EBITDA, should not be considered replacements for and should be read in conjunction with the GAAP financial measures.

We define Adjusted EBITDA as GAAP net loss adjusted to exclude: (1) interest expense, (2) interest income, (3) provision for income taxes, (4) depreciation and amortization, (5) stock-based compensation expense (5) derivative income (expense) and (6) certain other items management believes affect the comparability of operating results. Please see "Adjusted EBITDA" below for more information and for a reconciliation of Adjusted EBITDA to net income, the most directly comparable financial measure calculated and presented in accordance with GAAP.

 

IPSIDY INC AND SUBSIDIARIES

Reconciliation of Net Loss to Adjusted EBITDA 



 (Unaudited) 










 For the Year Ended 



 December 31, 2017 


 December 31, 2016 











 Net loss 


$           (17,481,629)


$            (9,851,403)






 Add Back: 










 Interest expense 


1,337,081


3,625,984

 Income taxes 


28,781


2,946

 Conversion of debt, derivative liability, and modifications 


4,106,652


(7,345,000)

 Depreciation and amortization 


475,211


421,694

 Write-off of asset 


212,862


225,862

 Stock compensation 


5,650,072


8,648,212






 Adjusted EBITDA (Non-GAAP) 


$            (5,670,970)


$            (4,271,705)

 

 

IPSIDY INC AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS



(Unaudited)






December 31,


December 31,




2017


2016







ASSETS

Current Assets:






Cash



$      4,413,822


$          689,105

Accounts receivable, net



165,929


138,359

Current portion of net investment in direct financing lease



52,790


44,990

Inventory, net



492,030


150,679

Other current assets



218,537


166,479

Total current assets



5,343,108


1,189,612







Property and equipment, net



209,719


115,682

Other Assets



1,243,531


358,343

Intangible Assets, net



2,878,080


3,474,291

Goodwill



6,736,043


6,736,043

Net investment in direct financing lease, net of current portion



618,763


674,015

Total assets



$    17,029,244


$     12,547,986







LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Current Liabilities:






Accounts payable and accrued expenses



$      1,447,185


$       1,687,900

Convertible notes payable, net



-


250,000

Derivative liability



-


8,388,355

Capital lease obligation, current portion



27,420


-

Notes payable, net, current portion



-


109,819

Deferred revenue



122,511


398,680

Total current liabilities



1,597,116


10,834,754







Long-term liabilities:






Convertible notes payable, net, less current maturities



-


3,051,603

Notes payable, net, less current maturities



2,375,720


2,245,596

Capital lease obligation, net of current portion



115,509


-

Derivative liability, net of current portion



-


9,668,276

Total long-term liabilities



2,491,229


14,965,475

        Total liabilities



4,088,345


25,800,229







Commitments and Contingencies 












Stockholders' Equity (Deficit):






Common stock, $0.0001 par value, 1,000,000,000 and 500,000,000 shares






authorized; 403,311,988 and 234,704,655 shares issued






and outstanding as of September 30, 2017 and December 31, 2016, respectively

40,331


23,470

Additional paid in capital



79,053,339


35,341,669

Accumulated deficit



(66,407,622)


(48,925,993)

Accumulated comprehensive income



254,851


308,611

Total stockholders' equity (deficit)



12,940,899


(13,252,243)

Total liabilities and stockholders' equity (deficit)



$    17,029,244


$     12,547,986

 

 

IPSIDY INC  AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

 (Unaudited)
















Year Ended







December 31,







2017


2016










Revenues:








Products and services




$      2,228,910


$       1,877,446

Lease income





74,696


52,492

Total revenues, net




2,303,606


1,929,938










Operating Expenses:







Cost of sales





589,254


492,237

General and administrative




13,026,188


14,243,363

Research and development




222,068


340,317

Depreciation and amortization



475,211


421,494

Total operating expenses




14,312,721


15,497,411










Loss from operations




(12,009,115)


(13,567,473)










Other Income (Expense):







(Loss) gain on derivative liabilities



(452,146)


7,345,000

 Gain on extinguishment of notes payable


2,802,234


-

 Loss on modification of derivatives



(319,770)


-

 Loss on modification of warrants



(158,327)


-

 Loss on settlement of notes payable



(5,978,643)


-

Interest expense





(1,337,081)


(3,625,984)

Other income (expense), net



(5,443,733)


3,719,016










Loss before income taxes




(17,452,848)


(9,848,457)










Income tax expense





28,781


2,946










 Net loss





$   (17,481,629)


$      (9,851,403)










Net Loss Per Share - Basic and Diluted 



$            (0.05)


$             (0.05)










Weighted Average Shares Outstanding - Basic and Diluted

338,485,301


217,570,666

 

 

IPSIDY INC AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS




                         (Unaudited)












Year Ended







December 31,







2017


2016

CASH FLOWS FROM OPERATING ACTIVITIES:






Net(loss) income 





$   (17,481,629)


$      (9,851,403)

Adjustments to reconcile net loss with cash used in operations:





Depreciation and amortization expense



475,211


421,494

Stock-based compensation




5,650,072


8,648,212

Common stock issued for services



140,151


311,103

Amortization of debt discount and debt issuance costs, net


937,133


3,165,079

Loss (gain) on derivative liability



452,146


(7,345,000)

Gain on settlement of notes payable



(2,802,234)


-

 Loss on modification of derivatives



319,770


-

 Loss on modification of warrants



158,327


-

 Loss on conversion of debt




5,978,643



 Write off of abandoned property



212,862


225,862

 Gain on sale of property






(3,681)

Changes in operating assets and liabilities:






Accounts receivable




(36,963)


674,952

Net investment in direct financing lease



47,452


28,939

Other current assets




(52,058)


(32,255)

Inventory





(354,227)


(194,473)

Accounts payable and accrued expenses



90,353


(254,560)

Deferred revenue





(276,169)


398,680

Net cash flows from operating activities



(6,541,160)


(3,807,051)










CASH FLOWS FROM INVESTING ACTIVITIES:






Purchase of property and equipment



(13,246)


(23,565)

Proceeds from sale of property and equipment





8,007

Investment in other assets including work in process



(894,435)


(283,813)

Cash acquired in acquisitions




-


419,042

Net cash flows from investing activities



(907,681)


119,671










CASH FLOWS FROM FINANCING ACTIVITIES:






Proceeds from issuance of notes payable and common stock


3,000,000


1,550,000

Proceeds from issuance of converible notes payable, common stock and warrants

-


1,375,000

Proceeds from issuance of notes payable, related parties


-


13,609

Proceeds from the sale of common stock and other



9,002,290


1,250,000

Proceeds from exercise of common stock warrants



26,400


-

Payment of debt and equity issuance cost



(750,975)


(229,423)

Principal payments on capital lease obligations



(59,819)


(120,242)

Principal payments on notes payable



(30,842)


(89,569)

Net cash flows from financing activities



11,187,054


3,749,375










Effect of foreign currencies




(13,496)


277,237










Net change in Cash





3,724,717


339,232

Cash, Beginning of Period




689,105


349,873

Cash, End of Period





$     4,413,822


$          689,105










Supplemental Disclosure of Cash Flow Information:






Cash paid for interest




$          22,192


$             11,051

Cash paid for income taxes




$          28,781


$               2,946










Non-cash Investing and Financing Activities:






Issuance of common stock for conversion of debt and related interest

$   21,609,673


$            21,122

Issuance of common stock in settlement of liability



$                    -


$            59,681

Issuance of common stock for debt issuance costs



$        224,460


$          257,696

Issuance of common stock with debt



$                    -


$          222,815

Issuance of warrants for inventory costs



$                    -


$            79,081

Reclassification of derivatives upon removal of price protection in warrants

$     7,614,974


$          692,850

Debt discount for fair value of warrants issued in connection with debt

$                    -


$          358,411

Debt disocunt for fair value of embedded conversion features


$                    -


$          290,425

Reclassification of inventory to net investment in direct financing lease

$                    -


$          747,944

Acquisition of equipment due to a capital lease



$        163,407


$                      -

Acquisition of FIN Holdings (2016):






Issuance of common stock as consideration



$                    -


$       9,000,000

Assumed liabilities




-


914,218

Inventory





-


(112,408)

Accounts receivable




-


(311,867)

Property and equipment




-


(100,339)

Intangible assets





-


(8,970,562)

Cash acquired





$                    -


$          419,042

 

Ipsidy Inc.  

Contacts:
Ipsidy Inc.   
Philip D. Beck, Chairman, CEO & President
[email protected]  
+1 (516) 274-8700

Thomas Szoke, Chief Technology Officer
[email protected]

Stuart P. Stoller, CFO
[email protected]

 

 

SOURCE Ipsidy Inc.


These press releases may also interest you

at 16:32
The wishes that Make-A-Wish grants wouldn't be possible without the support of countless "WishMakers" such as donors, volunteers, corporate partners, community advocates and more. "WishMakers" ? a term for anyone who steps up to take action...

at 16:30
Today, the Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health, announced a new appointment to the Canadian Centre on Substance Use and Addiction (CCSA) Board of Directors. Scott Elliott is appointed as...

at 16:28
The Rett Syndrome Research Trust (RSRT) is proud to announce its partnership with PMD Solutions, a leading provider of innovative healthcare technologies, in their upcoming biosensor validation study called VIBRANT. PMD Solutions will generously...

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31,...

at 16:20
AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended...

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced that its Board of Directors has unanimously approved plans to initiate a rights offering. The...



News published on and distributed by: